美国FDA-话题@MedSci

#美国FDA#

186篇内容 | 3862人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1551442, encodeId=143c15514425a, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤, objectType=article, longId=174421, objectId=3d441e442153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d441e442153, replyNumber=0, likeNumber=66, createdTime=2019-06-30, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d441e442153, moduleTitle=美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d441e442153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551441, encodeId=00b71551441fe, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=警惕！防晒霜安全吗美国FDA与临床医生产生分歧, objectType=article, longId=166709, objectId=d051166e098c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d051166e098c, replyNumber=0, likeNumber=64, createdTime=2019-05-25, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d051166e098c, moduleTitle=警惕！防晒霜安全吗美国FDA与临床医生产生分歧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d051166e098c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551440, encodeId=5e2f15514401b, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者, objectType=article, longId=166326, objectId=480a16632698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480a16632698, replyNumber=0, likeNumber=69, createdTime=2019-05-20, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480a16632698, moduleTitle=美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480a16632698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551439, encodeId=829015514393d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA接受Takeda申请皮下注射维多珠单抗，用于溃疡性结肠炎的维持治疗, objectType=article, longId=165924, objectId=85db165924d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85db165924d9, replyNumber=0, likeNumber=74, createdTime=2019-05-14, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85db165924d9, moduleTitle=美国FDA接受Takeda申请皮下注射维多珠单抗，用于溃疡性结肠炎的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85db165924d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551438, encodeId=747b1551438b5, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准**登革热疫苗，可在首次感染后注射, objectType=article, longId=165611, objectId=5224165611e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5224165611e0, replyNumber=0, likeNumber=55, createdTime=2019-05-09, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5224165611e0, moduleTitle=美国FDA批准**登革热疫苗，可在首次感染后注射, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5224165611e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551437, encodeId=cc8f155143ea5, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret, objectType=article, longId=165452, objectId=7fcf1654522f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fcf1654522f, replyNumber=0, likeNumber=82, createdTime=2019-05-07, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fcf1654522f, moduleTitle=美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fcf1654522f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551436, encodeId=47a4155143695, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定, objectType=article, longId=164502, objectId=df0c164502be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0c164502be, replyNumber=0, likeNumber=59, createdTime=2019-04-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0c164502be, moduleTitle=Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df0c164502be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551435, encodeId=7091155143523, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, objectType=article, longId=163717, objectId=ffde163e1796, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffde163e1796, replyNumber=0, likeNumber=0, createdTime=2019-04-07, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffde163e1796, moduleTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffde163e1796)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551434, encodeId=b0e8155143454, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, objectType=article, longId=162858, objectId=f5fa1628585f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5fa1628585f, replyNumber=0, likeNumber=95, createdTime=2019-03-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5fa1628585f, moduleTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5fa1628585f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551433, encodeId=c8a5155143356, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA发布氟喹诺酮类药物引起主动脉破裂的新警告, objectType=article, longId=162350, objectId=28b3162350ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28b3162350ab, replyNumber=0, likeNumber=64, createdTime=2019-03-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28b3162350ab, moduleTitle=美国FDA发布氟喹诺酮类药物引起主动脉破裂的新警告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28b3162350ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551432, encodeId=0c6a155143249, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%, objectType=article, longId=161821, objectId=d8a2161821d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8a2161821d7, replyNumber=0, likeNumber=89, createdTime=2019-03-08, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8a2161821d7, moduleTitle=2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8a2161821d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551431, encodeId=306315514311c, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=针对“换血疗法” 美国FDA已经发布声明你需要了解, objectType=article, longId=161597, objectId=a7f916159edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7f916159edd, replyNumber=0, likeNumber=45, createdTime=2019-03-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7f916159edd, moduleTitle=针对“换血疗法” 美国FDA已经发布声明你需要了解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7f916159edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551430, encodeId=ac391551430f4, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=22, createdTime=2019-03-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551429, encodeId=232a15514295c, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 , objectType=article, longId=161249, objectId=55e816124925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55e816124925, replyNumber=0, likeNumber=86, createdTime=2019-02-28, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55e816124925, moduleTitle=Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55e816124925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551428, encodeId=b1fc155142839, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, objectType=article, longId=161117, objectId=2dcd16111ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dcd16111ee7, replyNumber=0, likeNumber=64, createdTime=2019-02-27, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dcd16111ee7, moduleTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dcd16111ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551427, encodeId=985f155142e6e, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, objectType=article, longId=160893, objectId=8353160893a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8353160893a6, replyNumber=0, likeNumber=64, createdTime=2019-02-25, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8353160893a6, moduleTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8353160893a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551426, encodeId=7c741551426b0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=中国第一个获得美国FDA“突破性疗法”认证的抗癌新药到底好在哪？, objectType=article, longId=158826, objectId=ae6c15882697, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6c15882697, replyNumber=0, likeNumber=59, createdTime=2019-01-26, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6c15882697, moduleTitle=中国第一个获得美国FDA“突破性疗法”认证的抗癌新药到底好在哪？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae6c15882697)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551425, encodeId=b9a8155142588, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测, objectType=article, longId=158660, objectId=529c158660c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529c158660c2, replyNumber=0, likeNumber=73, createdTime=2019-01-24, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529c158660c2, moduleTitle=谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=529c158660c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551424, encodeId=d6fa1551424ab, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, objectType=article, longId=156675, objectId=905a1566e5bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=905a1566e5bb, replyNumber=0, likeNumber=74, createdTime=2018-12-27, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=905a1566e5bb, moduleTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=905a1566e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551423, encodeId=b4e4155142300, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA发布《真实世界证据方案框架》, objectType=article, longId=155478, objectId=32cb1554e8e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32cb1554e8e4, replyNumber=0, likeNumber=60, createdTime=2018-12-11, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32cb1554e8e4, moduleTitle=美国FDA发布《真实世界证据方案框架》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32cb1554e8e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

美国FDA

2020-05-29

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准daratumumab联合来那度胺和地塞米松治疗初治多发性骨髓瘤

2019-06-30

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

警惕！防晒霜安全吗美国FDA与临床医生产生分歧

2019-05-25

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准GATTEX用于治疗短肠综合症（SBS）儿童患者

2019-05-20

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA接受Takeda申请皮下注射维多珠单抗，用于溃疡性结肠炎的维持治疗

2019-05-14

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准**登革热疫苗，可在首次感染后注射

2019-05-09

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA首次批准儿童全基因型抗丙肝药物：艾伯维的Mayyret

2019-05-07

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定

2019-04-19

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者

2019-04-07

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请

2019-03-26

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA发布氟喹诺酮类药物引起主动脉破裂的新警告

2019-03-16

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

2018美国FDA仿制药批准报告：批准超1000个仿制药首仿药占10%

2019-03-08

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

针对“换血疗法” 美国FDA已经发布声明你需要了解

2019-03-05

zhouqu_8 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病

2019-03-02

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

Alkermes和Biogen宣布美国FDA接受了Diroximel富马酸盐治疗多发性硬化症的新药申请 

2019-02-28

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定

2019-02-27

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请

2019-02-25

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

中国第一个获得美国FDA“突破性疗法”认证的抗癌新药到底好在哪？

2019-01-26

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

谷歌Verily智能手表获美国FDA批准，可用于心电图节律检测

2019-01-24

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请

2018-12-27

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA发布《真实世界证据方案框架》

2018-12-11

科室
- - 订阅+
  - 更多科室
工具
服务